- These are not official programs of the American College of Rheumatology.
- All industry sessions will be available on-demand on the virtual meeting platform until March 10, 2022.
Events
Learn how UCB is committed to patients with BIMZELX® (bimekizumab-bkzx)!
Innovation Theater A
Developed and offered by UCB Commercial
A Snapshot of Rheumatology Innovation: Exploring the argenx Pipeline
Developed and offered by argenx.
Systemic Sclerosis: Connecting Clinical Insights, Biology, and Future Research
Innovation Theater B
Developed and offered by AstraZeneca.
Lupus Nexus: A Powerful Resource for Scientific, Clinical and Patient Communities
Developed and offered by Lupus Research Alliance.
Living with Sjogren’s: Understanding the Patient Experience
Developed and offered by Sjögren’s Foundation.
Building a Data Ecosystem to Advance Patient-Centered Clinical Trials
Developed and offered by Foundation for Sarcoidosis Research.
Beyond Disease Control: Exploring the Potential of Immune Reset In Autoimmune Disease Through CAR T Clinical Trials
Developed and offered by BMS.
Managing Active PsA Across Multiple Key Domains: A Clinical Discussion on Axial Involvement
Innovation Theater A
Developed and offered by Johnson & Johnson.
Rethinking Sjogren’s: TYK2 and Type I IFN Signaling in a Systemic, Heterogeneous Disease
Developed and offered by BMS.
The Right Patient, Right Time: Navigating the CAR T Clinical Trial Journey in SLE
Developed and offered by BMS.
New Data Can Start A New Conversation
Innovation Theater B
Developed and offered by Lilly USA, LLC
FT819: A Potentially Transformative Outpatient-Enabled CAR T-Cell Therapy Candidate for Systemic Lupus Erythematosus with or without Lupus Nephritis
Developed and offered by Fate Therapeutics.
Targeting Inflammatory Pathways in Knee Osteoarthritis: A New Way at Looking at an Old Disease
Developed and offered by Pacira Biosciences.
Make Rheum for Lungs: Treating Progressive Pulmonary Fibrosis in Your Patients
Innovation Theater A
Developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.
Identifying Treatment Opportunities for Patients With Lupus Nephritis
Innovation Theater B
Developed and offered by Genentech
Beyond Disease Control: Exploring the Potential of Immune Reset In Autoimmune Disease Through CAR T Clinical Trials
Innovation Theater B
Developed and offered by Lilly.
Preventing Progression in Lupus: Are You Intervening Early Enough?
Regency Ballroom Q
Developed and offered by GSK
Reframing Sjögren’s Disease: Patient perspectives and clinical context in a systemic and often progressive disease
Windermere Y
Developed and offered by Novartis Pharmaceuticals Corporation
Connecting the Evidence: Translational Science, Clinical Trials, and Real-World Data in SLE
Regency Ballroom P
Developed and offered by AstraZeneca.
Suspect. Detect. Act: Diagnosing and Treating Autoimmune Interstitial Lung Disease
Windermere Ballroom Z
Developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc.
Beyond the Joints: A Whole-Body Approach to Psoriatic Arthritis Care Through Integrated Obesity Management
Orlando Ballroom N
Provided by Clinical Care Options LLC dba Decera Clinical Education in partnership with the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Obesity Medicine Association (OMA). This activity is supported by an educational grant from Lilly.
The Pathogenesis of Sjögren’s Disease and Clinical Pearls on Diagnosis
Windermere Ballroom W
Developed and offered by Johnson & Johnson.
Making Waves in axSpA and HS: Connecting Diseases Through Shared Immune Pathways
Windmere Ballroom X
Developed and offered by UCB Medical
UPLIZNA: The First and Only FDA-Approved Treatment for IgG4-RD
Innovation Theater A
Developed and offered by Amgen.
Interstitial Lung Disease: Recognize Early, Act Early
Developed and offered by GSK.
Changing Course: Clinical Evidence From the First Head-to-Head Trial Powered to Evaluate the Superiority of Switching to a JAKi Versus Another TNFi After a Single TNF Failure
Innovation Theater B
Developed and offered by AbbVie.
The Clinical Investigation of In Vivo CAR T as a Potentially Scalable and Targeted Path to Immune Reset in Certain Autoimmune Diseases
Developed and offered by BMS.
Recognizing VEXAS Syndrome: From Clinical Suspicion to Diagnosis
Developed and offered by GSK.
Live Lightning Talk by CARRA
Developed and offered by CARRA.
The Right Patient, Right Time: Navigating the CAR T Clinical Trial Journey in SLE
Developed and offered by BMS.
Clinical Insights in Lupus and LN: Revisiting Long-Standing Perceptions with Emerging Evidence
Innovation Theater A
Developed and offered by GSK.
Understanding the CD40-CD40L Pathway, Clinical Heterogeneity, and Patient Experience in Sjögren’s Disease
Developed and offered by Amgen.
Caught in the Cycle: Relapse and Glucocorticoid Burden in ANCA-Associated Vasculitis
Developed and offered by Amgen.
Efficacy, Safety, and Dosing of an Oral Treatment Option for Active Psoriatic Arthritis
Innovation Theater B
Developed and offered by Bristol Myers Squibb
Farr Radioimmunoassay (RIA) Method Enhances Monitoring in Lupus with Quantitative Anti-dsDNA Antibody Measurements
Developed and offered by Labcorp.
Vagus-Mediated Neuroimmune Modulation for Rheumatoid Arthritis
Innovation Theater A
Developed and offered by SetPoint Medical.
Shared Immunopathology in PMR, GCA, and RA: The Central Role of IL-6
Innovation Theater B
Developed and offered by Sanofi.
Beyond the Joint: The Immunometabolic Burden of Obesity in Knee OA
Regency Ballroom P
Developed and offered by Eli Lilly and Company
Autoimmune Myositis Reframed: New Perspectives on Burden, Biology, and Clinical Outcomes
Regency Ballroom Q
Developed and offered by argenx.
A Closer Look at Psoriatic Arthritis With Axial Involvement
Windermere Ballroom W
Developed and offered by Johnson & Johnson.
Turning Complexity Into Clinical Clarity: Practical Approaches for the Comprehensive Assessment of Sjögren’s Disease
Windermere Ballroom X
Developed and offered by Novartis Pharmaceuticals Corporation.
Every Conversation Counts: Achieving Disease Control Across the Reproductive Journey in Women With SLE
Windermere Ballroom Y
Developed and offered by UCB Biopharma SRL.
Reframing Lupus Care: Emerging TYK2 Inhibitors and the Future of Treat-to-Target Management in SLE
Regency Ballroom O
Developed and offered by Bristol Myers Squibb.
What the First FDA-Approved Treatment for Fibromyalgia in Over 15 Years Means for Your Adult Patients
Innovation Theater A
Developed and offered by Tonix Pharmaceuticals.
Bridging the Age Gap: Recognizing MAS Before it is too Late
Innovation Theater B
Developed and offered by Sobi.
Immunoglobulin Therapy: Immune Modulation and Infection Prevention
Innovation Theater A
Developed and offered by Octapharma
Designed for Autoimmunity: Rese-Cel and the RESET Clinical Program
Innovation Theater B
Developed and offered by Cabaletta Bio.
IIMagine What’s Next in Myositis Care: Integrating Targeted Strategies to Advance Patient Outcomes
Regency Ballroom P
Developed and offered by PeerView Institute for Medical Eduation. Supported by argenx.
Treatment Advances in IgG4-Related Disease: Integrating Targeted Therapy to Improve Patient Outcomes
Regency Ballroom Q
Developed and offered by Med Learning Group. Supported by Amgen.
A Multidisciplinary Journey Through SLE Heterogeneity
Regency Ballroom O
Developed and offered by Viatris.
Targeting Upstream in Sjögren Disease: Building a Deeper Understanding of Disease and Investigational Therapies
Windermere Ballroom Z
Developed and offered by Vor Bio.
IgG4-RD in Focus: From Disease Burden to Emerging Clinical Evidence
Windermere Ballroom Y
Developed and offered by Zenas BioPharma.
Lupus Nephritis: New Treatments to Improve Patient Outcomes
Orlando Ballroom N
Developed and offered by Vindico. Supported by Genentech, a member of the Roche Group.
A Key Source of the Signal: Rethinking Lupus Skin and Joint Disease
Windermere Ballroom W
Developed and offered by Biogen.